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ORIGINAL ARTICLE
Introduction: The appropriate therapeutic strategy and postop-
erative management for patients with stage IA non–small-cell lung 
cancer (NSCLC) still remain a matter of debate because of the prog-
nostic heterogeneity of this population, including the risk of cancer 
recurrence. The objective of the current study was to identify the 
clinicopathological factors that affect overall prognosis and cancer 
recurrence of stage IA NSCLC.
Methods: We reviewed the data of 532 patients in whom complete 
resection of stage IA NSCLC had been performed. Overall survival 
and recurrence-free proportion (RFP) were estimated using the 
Kaplan–Meier method. RFP was estimated from the date of the pri-
mary tumor resection to the date of the ﬁrst recurrence or last follow-
up. We performed univariate and multivariate analyses to determine 
the independent prognostic factors.
Results: On multivariate analyses, three variables were shown to 
be independently signiﬁcant recurrence risk factors: histological 
differentiation (hazard ratio [HR] = 1.925), blood-vessel invasion 
(HR = 1.712), and lymph-vessel invasion (HR = 1.751). On subgroup 
analyses combining these risk factors, the 5-year RFP was 91.3% 
for patients with no risk factors, 79.5% for those with either poorly 
differentiated carcinoma or vascular invasion, (p < 0.001 for both), 
and 62.9% for those with both poorly differentiated carcinoma and 
vascular invasion (p = 0.068).
Conclusion: These results indicated that vascular invasion and tumor 
differentiation have a signiﬁcant impact on the prediction of cancer 
recurrence in patients with stage IA NSCLC. Patients with these pre-
dictive factors of recurrence may be good candidates for adjuvant 
chemotherapy.
Key Words: Prognostic factor, Non–small-cell lung cancer, Recurrence, 
Stage IA, Vascular invasion, Tumor differentiation.
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Anjana
The tumor, node, metastasis (TNM) staging system for non–small-cell lung cancer (NSCLC) is currently the 
best confirmed predictor of survival and guide for treatment. 
NSCLC patients with pathologic stage IA disease have the 
best chance of survival, and resection is standard in such 
cases. However, even after curative resection, the 5-year sur-
vival rate is between 80% and 87% in pathologic stage IA 
patients as shown in large-scale Japanese lung cancer stud-
ies,1–3 and recent data from the lung cancer staging project of 
the International Association for the Study of Lung Cancer 
revealed a 5-year survival rate of 73% for pathological stage 
IA patients.4 Therefore, up to 10% of patients with stage IA 
NSCLC have recurrence after surgery, even in cases with 
early-stage disease.
Many studies of resected specimens have been per-
formed to determine various clinicopathological prognostic 
factors other than the pathologic stage for these patients, such 
as sex, age,5 smoking history,6 serum level of carcinoembry-
onic antigen (CEA),7 extent of operation,5 tumor size, vascular 
invasion,7–18 and the grade of differentiation of the tumor.14,17,19 
Patients, including those with stage IA NSCLC, who have 
such factors may be good candidates for receiving systemic 
therapy such as adjuvant chemotherapy. The objective of the 
present study was to identify the clinicopathological factors 
that affect overall prognosis and cancer recurrence of stage IA 
NSCLC in a single institution.
PATIENTS AND METHODS
Patients
From January 1990 to December 2007, a total of 1973 
patients underwent complete pulmonary resection for NSCLC 
at our hospital. Complete resection was deﬁned as cancer-
free surgical margins both grossly and histologically. All the 
patients underwent radical surgical resection and systematic 
mediastinal lymph node dissection. Of these, 674 patients 
with consecutive pathologic stage IA NSCLC were identiﬁed 
in our departmental database. The number of resected lymph 
nodes ranged from one to 49, with a mean of 15. We excluded 
142 patients who had undergone preoperative chemotherapy 
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or radiotherapy (n = 17), postoperative treatment including 
chemotherapy or chemoradiotherapy (n = 105), and those 
who had low-grade malignant tumors including carcinoids, 
mucoepidermoid carcinomas, or adenoid cystic carcinomas 
(n = 20). The remaining 532 patients comprised the subjects 
of this study.
Preoperative evaluation included physical examination, 
chest radiography, computed tomography (CT) of the chest 
and abdomen, bone scintigraphy, blood examination, and 
since the early 2000s, positron-emission tomography (PET) 
scan (recently performed as integrated PET-CT scan). Most 
patients were postoperatively evaluated by physical exami-
nation, chest radiography, and CT of the chest and abdomen 
to confirm relapse. In some patients, we used PET-CT, mag-
netic resonance imaging or bone scintigraphy to detect recur-
rence. The disease stage was determined in accordance with 
the 7th edition of the TNM classification for lung and pleural 
tumors.20
Histopathology
The available pathology slides from all 532 surgical spec-
imens were reviewed in this study. After fixing the specimens 
with either 10% formalin and embedding them in paraffin, 
serial 4-μm sections were stained with hematoxylin and eosin 
and by elastica van Gieson (EvG) to visualize elastic fibers. 
Histologic subtypes of lung cancer were determined accord-
ing to World Health Organization classiﬁcation.21 The histo-
logical tumor grade was categorized as well- differentiated, 
moderately differentiated, or poorly differentiated  carcinoma 
according to the degree of structural and cytologic atypia.
Blood vessels were identiﬁed by the presence of eryth-
rocytes in the lumen and/or an endothelial cell lining and/or 
the presence of elastic tissue around larger vessels. Sections 
stained by EvG were examined for the presence of blood-
vessel invasion. The presence of blood-vessel invasion was 
determined by identifying conspicuous clusters of intravascu-
lar cancer surrounded by an elastic layer.
Lymph-vessel invasion was determined to be present 
when tumor cells floating in lymphatic vessels with no sup-
porting smooth muscles or elastic fibers were identified. We 
confirmed that lumens within the bronchovascular bundle, 
subpleural, and intralobular pleural space were lymphatic ves-
sels by immunostaining with anti-D2-40 antibody.
Data Collection
Clinical characteristics were retrieved from avail-
able clinical records. The following clinicopathological 
factors were assessed in the retrospective prognostic analy-
sis: age (dichotomized at the median age of 64 years), sex, 
smoking status, preoperative serum CEA level (cutoff at 
the normal upper limit of 5 ng/ml), tumor size, tumor dif-
ferentiation (well or moderate versus poor), blood-vessel 
invasion (absence versus presence), lymph-vessel invasion 
(absence versus presence), histology (adenocarcinoma versus 
other), tumor laterality, and extent of resection (single-lobe 
lobectomy versus more extensive resection; bilobectomy or 
pneumonectomy).
Statistical Analysis
Overall survival (OS) was measured from the date of 
surgery to the date of death from any cause or the date on 
which the patient was last known to be alive. The length 
of the recurrence-free period was calculated in months 
from the date of resection to the date of the first recurrence 
or last follow-up showing no recurrence. To calculate the 
recurrence-free proportion (RFP), patients who died with-
out recurrence or who were known to have no recurrence at 
the date of last contact were censored. OS and RFP curves 
were plotted using the Kaplan–Meier method, and differ-
ences in variables were determined using the log-rank test. 
Categorical comparison was performed using the Pearson 
FIGURE 1.  A, Overall survival curves of patients with T1a or 
T1b disease. B, Recurrence-free proportion curves of patients 
with T1a or T1b disease.
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χ2 test. Multivariate analyses were performed using the Cox 
proportional hazards regression model. All tests were two-
sided, and p values of less than 0.05 were considered to 
indicate a statistically significant difference. Statview 5.0 
software (SAS Institute Inc., Cary, NC) was used for statis-
tical analyses. Data collection and analyses were approved 
and the need to obtain written informed consent from each 
patient was waived by the institutional review board of our 
institution.
RESULTS
The median follow-up for survivors was 5.1 years. 
Figure 1A and B show the OS and RFP curves of 316 patients 
with T1aN0M0 NSCLC and 216 patients with T1bN0M0 
NSCLC. For those patients with T1aN0M0 NSCLC and those 
with T1bN0M0 NSCLC, the 5-year OS rates were 87.1% and 
77.2% (p = 0.013), respectively, whereas the 5-year RFPs 
were 88.6% and 78.6% (p = 0.056), respectively.
Table 1 shows the 5-year OS proportions and RFPs 
according to the clinicopathological characteristics of the stage 
IA NSCLC patients. On univariate analysis, nine variables 
were found to be signiﬁcantly associated (p < 0.05) with 
poorer OS: older age, male sex, smoking history, T1b, poorly 
differentiated carcinoma, blood-vessel invasion, lymph- 
vessel invasion, nonadenocarcinoma, and type of surgery 
(bilobectomy or pneumonectomy). For RFP, five variables 
(male sex, poorly differentiated carcinoma, blood-vessel 
invasion, lymph-vessel invasion, and nonadenocarcinoma) 
were identified as statistically signiﬁcant factors on univariate 
analysis.
A multivariate Cox proportional hazards model demon-
strated that older age (hazard ratio [HR] = 1.936; p < 0.001), 
male sex (HR = 2.096; p = 0.005), tumor size (HR = 1.501; 
p = 0.045), poorly differentiated carcinoma (HR = 1.632; p = 
0.028), lymph-vessel invasion (HR = 1.579; p = 0.042), and 
nonadenocarcinoma (HR = 1.704; p = 0.016) were statistically 
significant predictors of OS (Table 2). Poorly differentiated 
carcinoma (HR = 1.925; p = 0.006), blood-vessel invasion 
(HR = 1.712; p = 0.020), and lymph-vessel invasion (HR = 
1.751; p = 0.017) were identified as statistically significant 
predictors of cancer recurrence (Table 3). Figures 2A, B, and C  
show the RFP curves of patients with stage IA NSCLC 
according to tumor differentiation, blood-vessel invasion, 
and lymph-vessel invasion, respectively. Table 4 shows the 
results of 5-year RFP of patients in each T subclassification 
(T1a and T1b) according to these significant predictors of can-
cer recurrence.
Subgroup analysis with a combination of these 
recurrence predictive factors in the patients with stage IA 
NSCLC revealed 5-year RFPs of 91.3%, 79.5%, and 62.9% for 
patients with no risk factor, poorly differentiated carcinoma 
or vascular invasion (blood-vessel invasion or lymph-vessel 
TABLE 1.  Patient Characteristics and Univariate Analysis of 
Survival and Recurrence
Variable
No. of 
Patients
5-Yr  
OSP (%) p Value
5-Yr  
RFP (%)
p  
Value
Age (yrs: median 64)
 < 64 279 88.9 84.2
 ≥ 64 253 76.6 < 0.001 85.3 0.946
Sex
 Male 290 77.7 81.4
 Female 242 89.6 < 0.001 88.4 0.009
Smoking status
 Ever smoker 279 81.5 82.6
 Never smoker 253 84.9 0.039 86.8 0.102
CEA (ng/ml: NUL of 5)
 < 5 447 83.7 85.2
 ≥ 5 59 75.9 0.108 77.2 0.212
Tumor size
 T1a (≤ 2.0 cm) 316 87.1 88.6
 T1b (≥ 2.1 cm) 216 77.2 0.013 78.6 0.056
Differentiation
 Well or moderate 425 86.4 87.7
 Poor 96 71.4 < 0.001 71.8 < 0.001
Blood-vessel invasion
 Absent 402 86.2 88.1
 Present 116 72.1 0.002 71.3 < 0.001
Lymph-vessel invasion
 Absent 392 85.4 87.1
 Present 122 76.4 0.003 76.1 0.001
Histology
 Adenocarcinoma 439 86.6 86.6
 Nonadenocarcinoma 93 66.3 < 0.001 74.3 < 0.001
Tumor laterality
 Right 357 82.9 84.3
 Left 175 83.6 0.685 85.4 0.732
Type of surgery
 Single-lobe  
lobectomy
510 84.0 84.5
 More extensive 
resection (more 
than bilobectomy)
22 66.7 0.046 88.7 0.946
OSP, overall survival proportion; RFP, recurrence-free proportion; NUL, normal 
upper limit; CEA, preoperative serum carcinoembryonic antigen level.
TABLE 2.  Multivariate Cox Proportional Hazards Regression 
Analysis of Overall Survival
Variable Risk Factors
Hazard 
Ratio
95% 
Confidence 
Interval
 p  
Value
Age ≥ 64 1.936 1.314–2.852 < 0.001
Sex Male 2.096 1.251–3.510 0.005
Smoking status Ever smoker 1.219 0.781–1.901 0.383
Tumor size T1b (≥ 2.1 cm) 1.501 1.009–2.233 0.045
Differentiation Poor 1.632 1.054–2.527 0.028
Blood-vessel 
invasion
Present 1.169 0.749–1.827 0.492
Lymph-vessel 
invasion
Present 1.579 1.017–2.449 0.042
Histology Nonadenocarcinoma 1.704 1.103–2.632 0.016
Type of surgery More extensive 
resection (more 
than bilobectomy)
1.981 0.984–3.984 0.055
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invasion), and both poorly differentiated carcinoma and 
vascular invasion, respectively (Fig. 3A). The differences in 
RFP were statistically significant between patients without 
any risk factors (A group) and those with poorly differentiated 
carcinoma or vessel invasion (B group) (p < 0.001). The 5-year 
RFP of patients with both poorly differentiated carcinoma and 
vascular invasion (C group) tended to be unfavorable compared 
with that of patients in the B group, but the difference was 
not statistically significant (p = 0.068). In patients with T1a, 
the 5-year RFP of patients without any risk factors (A group) 
was statistically different from that of patients with poorly 
differentiated carcinoma or vessel invasion (B group) (92.0% 
versus 83.7% in A and B, respectively; p = 0.002), whereas 
TABLE 3.  Multivariate Cox Proportional Hazards Regression 
Analysis of Cancer Recurrence
Variable Risk Factors
Hazard 
Ratio
95% 
Confidence 
Interval
 p  
Value
Sex Male 1.171 0.747–1.834 0.492
Differentiation Poor 1.925 1.210–3.063 0.006
Blood-vessel 
invasion
Present 1.712 1.088–2.694 0.020
Lymph-vessel 
invasion
Present 1.751 1.103–2.779 0.017
Histology Nonadenocarcinoma 1.615 0.994–2.623 0.053
FIGURE 2. A, Recurrence-free proportion curves according to tumor differentiation. B, Recurrence-free proportion curves 
according to blood-vessel invasion. C, Recurrence-free proportion curves according to lymph-vessel invasion.
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no significant difference was shown between patients in the B 
group and those with both poorly differentiated carcinoma and 
vascular invasion (C group; 79.4% at 5-year RFP for C group; 
p = 0.812) (Fig. 3B). The RFP curves for T1b patients of the 
A, B, and C groups were shown in Fig. 3C. The differences 
in recurrence were statistically significant between A and B 
(89.6% versus 75.1% at 5-year RFP in A and B, respectively; 
p = 0.006), B and C (43.3% at 5-year RFP for the C group; 
p = 0.002).
We tested for a correlation between histological grade 
or vascular-invasion status and clinicopathological variables 
in stage IA patients. A comparison of variables between 
well- or moderately differentiated carcinoma and poorly 
differentiated carcinoma groups showed that a statistically 
significant difference in the prevalence of poorly differenti-
ated carcinoma was seen in patients of male sex (p < 0.001), 
those who were smokers (p < 0.001) those in whom vascular 
invasion was present (p < 0.001), and those who had nonad-
enocarcinoma histology (p < 0.001). Vascular invasion was 
significantly associated with male sex (p = 0.035), smoking 
(p = 0.001), T1b (p < 0.001), and poorly differentiated car-
cinoma (p < 0.001) (data not shown).
Table 5 shows the number of patients with recurrence 
and their initial recurrence pattern according to histologi-
cal grade and vascular-invasion status. The proportion of 
patients who developed distant metastases was higher in these 
recurrence predictive factor positive populations than in the 
negative populations (histological grade; p = 0.048, vascular 
invasion; p = 0.024).
DISCUSSION
We set out to identify the clinicopathological factors 
that affect overall prognosis and cancer recurrence of stage 
IA NSCLC. Curative surgical resection is the most effective 
therapy for patients with stage IA NSCLC. However, a 
considerable number of patients develop recurrence, which 
results in cancer death. Previous studies have reported the 
following factors to be associated with a poor prognosis in 
patients with stage IA NSCLC: tumor size,5 preoperative 
serum CEA level,7 lymph-vessel invasion,18 blood-vessel 
invasion,7,13–15,17 and histological grade.14,17,19 In addition, 
according to the Surveillance, Epidemiology, and End Result 
Program database, age, sex, and extent of resection are also 
important prognostic factors.22 However, prognostic factors 
such as age and sex do not accurately predict or explain 
recurrence in patients with stage IA NSCLC. Therefore, we 
focused on the risk factors for recurrence and unfavorable OS 
in the present study. When describing the survival experience 
of a group of patients, the OS parameter is typically used. 
However, OS is affected by death resulting from causes 
other than lung cancer itself, including complications and 
comorbidities, and is considered to be affected by treatment 
after relapse. For example, epidermal growth factor receptor 
tyrosine kinase inhibitors are highly effective against mutated 
epidermal growth factor receptor recurrent NSCLC patients, 
suggesting potential improvements in postoperative survival 
regardless of surgery effect. Therefore, in evaluating pure 
surgical impact on the natural history of early-stage NSCLC, 
we consider that RFP may be a better prognostic indicator than 
OS. On multivariate analyses, we identiﬁed five independently 
signiﬁcant predictors for poor prognosis: older age (HR = 
1.936), male sex (HR = 2.096), tumor size (HR = 1.501), poorly 
differentiated carcinoma (HR = 1.632), lymph-vessel invasion 
(HR = 1.579), and nonadenocarcinoma (HR = 1.704); we also 
identified three predictors of recurrence: poorly differentiated 
carcinoma (HR = 1.925), blood-vessel invasion (HR = 1.712), 
and lymph-vessel invasion (HR = 1.751). The present study 
showed that independent predictive factors of poor survival 
were slightly different from predictive factors of recurrence.
Several authors reported that patients with poor dif-
ferentiated carcinomas after resection had a higher risk of 
recurrence and death.14,23,24 Although the histological grad-
ing system may provide useful information in deﬁning the 
aggressiveness of tumors and has a signiﬁcant impact on 
the survival of patients,19 the four-tiered system of grading 
(well-differentiated, moderately differentiated, poorly differ-
entiated, and undifferentiated carcinomas) for lung cancer 
is assumed to lack objectivity, because no original criteria 
have been developed for standardizing lung cancer histology. 
However, the current result indicates that poor differentiation 
contributes to unfavorable clinical outcome, suggesting that 
this factor may be a useful indicator of a need for postopera-
tive adjuvant chemotherapy in patients with stage IA NSCLC. 
Consistent grading criteria need to be established for repro-
ducible assessment.
Blood-vessel invasion is considered to be a funda-
mental step in hematogenous metastasis. The presence of 
blood-vessel invasion was previously found to be a strong 
TABLE 4.  5-Year Recurrence-Free Proportion for Each 
T Subclassification According to Histological Grade and 
Vascular-Invasion Status
T-Factor category No. of Patients 5-Yr RFP (%)  p Value
T1a (≤ 2.0 cm)
 Well/mod. 249 90.3
 Poor 60 83.8 0.126
T1b (≥ 2.1 cm)
 Well/mod. 176 83.7
 Poor 36 51.3 < 0.001
T1a (≤ 2.0 cm)
 BVI (−) 265 90.2
 BVI (+) 44 77.5 0.005
T1b (≥ 2.1 cm)
 BVI (−) 137 83.8
 BVI (+) 72 67.0 0.011
T1a (≤ 2.0 cm)
 LVI (−) 252 90.2
 LVI (+) 54 79.4 0.003
T1b (≥ 2.1 cm)
 LVI(−) 140 81.4
 LVI (+) 68 73.2 0.181
RFP, recurrence-free proportion; Well/mod., well- or moderately differentiated 
carcinoma; Poor, poorly differentiated carcinoma; BVI, blood-vessel invasion; LVI, 
lymph-vessel invasion.
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independent unfavorable prognostic factor, and vascular 
invasion should be considered for inclusion in the staging 
criteria and indications for adjuvant chemotherapy.10,11,13 
Fujisawa et al.25 demonstrated that blood-vessel invasion is 
a very important prognostic factor in resected NSCLCs with 
intrapulmonary metastasis, and may correlate with the ana-
tomical aspect of pulmonary metastasis. The current study 
also suggests that the presence of blood-vessel invasion is 
a signiﬁcant risk factor for recurrence in stage IA NSCLC 
patients.
To identify blood-vessel invasion more accurately, we 
used hematoxylin and eosin and EvG stains to visualize elas-
tic fibers in all cases. We recommend the routine use of elastic 
stains in the pathological evaluation of lung cancer, not only 
for the determination of visceral pleural invasion but also for 
the determination of blood-vessel invasion, particularly in 
patients with stage IA NSCLC.
Lymph-vessel invasion has been reported to be an inde-
pendent indicator of cancer invasiveness and poor prognosis in 
most studies that included this factor in their analyses.9,18,26,27 
The present study shows that as it is for histological grade, 
lymph-vessel invasion was a significant predictor of both poor 
prognosis and cancer recurrence, surpassing tumor size in 
pathologic stage IA NSCLC.
Recent randomized controlled trials have demon-
strated the usefulness of postoperative adjuvant chemother-
apy in stage IB to IIIA NSCLC patients who have undergone 
complete resections.28–30 Although surgery alone remains the 
FIGURE 3. A, Recurrence-free proportion curves for all stage IA; B, T1a; and C, T1b patients with well- or moderately differen-
tiated carcinoma and no vascular invasion (curve A), poorly differentiated carcinoma or vascular invasion (curve B), and both 
poorly differentiated carcinoma and vascular-invasion (curve C).
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standard treatment for patients with stage IA NSCLC, larger 
studies on resected cases comparing uracil-tegafur adjuvant 
chemotherapy versus observation showed that uracil-tegafu-
rimproved survival for patients with stage I adenocarcinoma, 
and also showed a clear survival benefit in the T1-disease 
subgroup of patients with a tumor of diameter more than 
2 cm.31,32 However, tumor size might not be the only fac-
tor found to have a benefit on adjuvant chemotherapy after 
complete resection of stage IA NSCLC. In the present study, 
when we divided the study population into A (patients with-
out any risk factors), B (those with either poorly differen-
tiated carcinoma or vascular invasion), and C (those with 
both poorly differentiated carcinoma and vascular invasion) 
groups, the 5-year RFP of all stage IA patients were 91.3%, 
79.5%, and 62.9%, respectively. In particular, the subgroup 
analysis of patients with stage IA disease stratiﬁed by tumor 
size showed a 5-year RFP of 43.3% for the T1b C group. 
These results indicated high-risk small-tumor N0 patients, 
identiﬁed by factors other than tumor size, such as tumor dif-
ferentiation and vascular invasion, may be good candidates 
for adjuvant chemotherapy.
This study has limitations and biases that should be 
mentioned. As a retrospective single-institute study, patient-
selection bias and time-trend bias regarding the diagnosis for 
cancer recurrence might be inevitable compared with multi-
institutional prospective study. Moreover, the definition of an 
ipsilateral lung metastasis as a local recurrence also generated 
inherent bias while allowing the differentiation of a new pri-
mary lung cancer from a recurrent NSCLC.
The anatomical extent of disease, as described by the 
TNM for lung and pleural tumors, remains the most power-
ful prognostic instrument in NSCLC. A challenge for the 
future will be to integrate the TNM with specific patho-
logical factors, such as vascular-invasion status or tumor 
differentiation, to create a composite prognostic index for 
NSCLC.
CONCLUSION
Even though most patients comprised an early-staging 
subset, those with stage IA NSCLC comprised a heterogeneous 
group with different prognoses and risk of cancer recurrence. 
The current study demonstrates that vascular-invasion status 
and tumor differentiation were far more powerful recurrence 
predictive factors than tumor size, and this information can be 
useful for the selection of the appropriate therapeutic strategy, 
including adjuvant chemotherapy, which can be tailored to 
the individual patient’s risk of developing recurrence.
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